GlaxoSmithKline PLC — Director's Dealing 2017

Feb 9, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 5449W

GlaxoSmithKline PLC

09 February 2017

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Sir Philip Hampton

b)

Position/status

Non-Executive Chairman

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.55	924.285

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-08

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Professor Sir Roy Anderson

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.55	1,850.161

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-08

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr Vindi Banga

b)

Position/status

Senior Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.55	271.263

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-08

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Vivienne Cox

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.55	3.951

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-08

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms Lynn Elsenhans

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053

b)

Nature of the transaction

Acquisition of notional ADSs following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
$39.46	1,177.411

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-08

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms Judy Lewent

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

b)

Nature of the transaction

Acquisition of notional ADSs following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
$39.46	626.140

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-08

f)

Place of the transaction

n/a

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr Urs Rohner

b)

Position/status

Independent Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882 

b)

Nature of the transaction

Acquisition of notional Ordinary Shares following the annual reinvestment of dividends paid to shareholders throughout 2016 under the share allocation arrangements for Independent Non-Executive Directors.

c)

Price(s) and

volume(s)

Price(s)	Volume(s)
£15.55	186.803

d)

Aggregated information

Aggregated volume Price

n/a (single transaction)

e)

Date of the transaction

2017-02-08

f)

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDKLFBDLFXBBF